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Several approaches to the production of vaccines to human herpesviruses have been proposed. Subunit
vaccines, subunits delivered by live vectors, and rationally attenuated vaccines have all been shown to be
efficacious in animal models but suffer from uncertainties as to the roles of individual genes involved in
pathogenesis and the most relevant components of the immune response required for protection in humans
and the target antigens involved. With these problems in mind, we examined the vaccine potential of a fully
disabled herpes simplex virus type 1 mutant that is capable of only a single round of replication, since a virus
of this type should induce the full spectrum of immune responses but has no pathogenic potential. A virus has
been described which lacks essential glycoprotein H (gH) and can be propagated in a cell line which supplies
gH in trans (A. Forrester, H. Farrell, G. Wilkinson, J. Kaye, N. Davis-Poynter, and T. Minson, J. Virol.
66:341-348, 1992). Infection of normal cells with this mutant is indistinguishable from a wild-type infection,
except that the resulting progeny are gH negative and noninfectious: the virus is self-limiting. Infection of mice
by the ear pinna route was similarly self-limiting in that input infectivity decreased rapidly at the inoculation
site and no infectivity was detected in sensory ganglia. Animals given a wide range of doses of the gH-negative
mutant produced both humoral and T-cell responses to herpes simplex virus type 1 and proved solidly resistant
to challenge with a high dose of wild-type virus. The gH-negative mutant is presumably capable of establishing
a latent infection, but since no infectious virus was detected in numerous attempts to reactivate the mutant, the
risk of a pathogenic outcome is minimal.
There is ample evidence, based primarily on studies using
animal models, that both the humoral and cell-mediated arms
of the immune response can function in the prevention and
control of herpes simplex virus (HSV) primary and recurrent
infections (14, 20). Thus, a number of studies have demon-
strated that administration of passive antibody modulates HSV
type 1 (HSV-1) infection in mice (18, 21); nevertheless,
B-cell-suppressed mice recover normally from infection (9,
22). A variety of immunization and vaccination protocols have
been effective in protecting rodents from HSV-1 infection.
These include administration of inactivated virions or infected
cell extracts, immunization with purified or recombinant gly-
coproteins, or vaccination with antigens delivered by live
vectors (reviewed in reference 4), but there is conflicting
evidence as to the major protective antigens and the immune
mechanism involved in the resulting protection. Furthermore,
given the relative ease with which protection can be achieved,
particularly in inbred mouse strains, there is significant doubt
as to the relevance of the mechanisms for immunity to HSV-1
in humans. In the face of this uncertainty as to the nature of
the protective immune response to HSV-1 in humans, the
development of rationally attenuated vaccines offers some
attraction, because live herpesvirus vaccines have proved suc-
cessful against veterinary diseases of economic importance (5,
17) and attenuated vaccines elicit a natural immune response,
thus reducing the need, in vaccine design, for a detailed
understanding of the immune response to infection. The
* Corresponding author. Mailing address: Division of Virology,
Department of Pathology, University of Cambridge, Level 5, Adden-
brookes Hospital, Cambridge, CB2 2QQ, United Kingdom. Phone: 44
223 336921. Fax: 44 223 336926. Electronic mail address: hef@mbfs.
bio.cam.ac.uk.
complexity of the HSV genome and the presence of a large
number of genes that are dispensable for growth in vivo
provide a variety of opportunities for rational attenuation.
Deletion or interruption of a number of genes, including the
thymidine kinase gene (6), several dispensable glycoprotein
genes (2, 24), and the protein kinase gene (16), has yielded
viruses with attenuated phenotypes that elicit a protective
response in experimental animals, but we cannot be certain
that these viruses will prove equally attenuated in humans. An
alternative approach to attenuation is the use of a fully
disabled virus that is replication defective. Although viruses of
this type synthesize only a subset of viral proteins and are
unable to produce virus particles, Nguyen et al. (15) showed
that HSV-1 mutants lacking either immediate-early gene ICP4
or ICP27 or early gene ICP8 were capable of eliciting T-cell
responses in BALB/c mice and were capable of protecting mice
from subsequent lethal intraperitoneal challenge with wild-
type HSV-1. Replication-incompetent viruses of this type,
however, fail to replicate the viral genome and, in conse-
quence, do not synthesize significant quantities of late proteins,
many of which are known to elicit protective immune re-
sponses (11, 19, 23). An alternative approach is to make use of
a virus that is replication competent but produces noninfec-
tious particles by virtue of the absence of a single essential
virion protein. A single-cycle virus with these characteristics
should present all of the virus-specific proteins, apart from the
absent one, to all arms of the immune response.
We have described previously the construction of an HSV-1
mutant in which glycoprotein H (gH) coding sequences are
replaced with the Escherichia coli lacZ gene and which is
propagated in a cell line supplying gH in trans (7). Infection of
normal cells results in a complete lytic cycle and the production
and secretion of normal numbers of noninfectious enveloped
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virions. We therefore decided to investigate the ability of this
virus to induce a protective response in mice by a single-cycle
infection.
MATERUILS AND METHODS
Viruses. The parent HSV-1 strain used in all of the experi-
ments was the SC16 strain and is hereafter referred to as
wtSC16. This virus was propagated on BHK-21 cells as de-
scribed previously (6). The construction of two HSV-1 mutants
derived from the SC16 parental strain in which the E. coli lacZ
gene replaced either US5 coding sequences (SC16AUS5) or
gH coding sequences (SC16AgH) has also been previously
described. The SC16AUS5 mutant is indistinguishable from
the parent virus with respect to growth and dissemination in
vitro (7, 25) and in vivo (1) and was used to facilitate detection
of virus-infected cells in mice. The SC16AgH mutant was
propagated on a supporting Vero cell line (F6) which supplies
gH in trans upon infection with HSV-1 (7). Thus, progeny
virions are phenotypically gH positive (having derived cellular
gH) and possess a particle-to-PFU ratio equivalent to that of
the wtSC16 virus. Viruses used for in vivo experiments were
partially purified by the following method. Extracellular virus
was recovered from cell cultures infected 48 h previously at a
multiplicity of infection of 0.01 and centrifuged for 90 min at
85,000 x g for 1 h. The virus pellets were resuspended in 3 ml
of TES (1 mM Tris [pH 7.4], 1 mM EDTA, 100 mM saline,
0.5% fetal calf serum) and loaded onto discontinuous 20 to
40% sucrose gradients. Following centrifugation at 25,000 x g
for 1 h, the viruses were harvested from the 20 to 40%
interface, diluted in TES, and centrifuged at 85,000 x g for 1
h. The virus pellets were resuspended in TES, and aliquots
were stored at -70°C. Purified wtSC16 was inactivated with
,B-propiolactone (0.05% [vol/vol]; 30 min at room tempera-
ture); the absence of live virus was demonstrated by plaque
assay.
Mice. Four-week-old female BALB/c mice were obtained
from Tucks Ltd. and inoculated at 5 to 6 weeks of age. Lightly
anesthetized mice were vaccinated by scarification of the left
ear pinna with an inoculum of either live or inactivated purified
virus in 2 ,ul of phosphate-buffered saline (PBS). Control mice
were inoculated with 2 ,ul of PBS only. At 14 days after
vaccination, mice were challenged by infection of the right ear
with wtSC16 at the doses indicated in the figure legends.
Measurement of virus titers in mouse tissues. Ear pinnae
and pooled innervating sensory ganglia (CII, CIII, and CIV)
were dissected and stored at - 70°C. Samples were later
homogenized and assayed for the presence of virus on BHK-21
or F6 cells as described previously (6).
Enzatic detection of SC16AUS5 and SC16AgH mutants
in cells infected in vitro and in vivo. The method used to detect
,3-galactosidase in cells infected in vitro with recombinant
viruses carrying the lacZ gene with the substrate 5-bromo-4-
chloro-3-indolyl-13-D-galactopyranoside (X-Gal) has been pre-
viously described (7). The same procedure was used to detect
the mutants in 5-,um frozen sections of ear pinnae from
inoculated mice, except that as a final step, the tissue was
counterstained with hematoxylin and eosin.
Detection of neutralizing antibodies to HSV-1. Neutralizing
antibodies were detected by a plaque reduction assay in the
presence of 5% fresh guinea pig serum as a source of comple-
ment. Individual serum samples were serially diluted in 500-,u
volumes and incubated with an equal volume of wtSC16 (103
PFU/ml) for 1 h at 37°C. Nonneutralized virus at the end of the
incubation was detected by plaque assay on BHK-21 cells. The
titer was calculated as the reciprocal dilution of serum required
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FIG. 1. Clearance of HSV-1 lacZ insertional mutants in the ears
and ganglia of mice. Groups of four mice were infected with either
SC16AgH (0) or SC16AUS5 (-), and virus titers were measured on
days 1, 2, 3, 4, 5, and 7 postinfection (P.I.). Virus titers in mice infected
with the SC16AgH mutant were determined on F6 cells, while titers in
mice infected with the SC16AUS5 mutant were assayed on BHK-21
cells. The data are presented as geometric means with the standard
errors of the means. All virus was of the j3-galactosidase-positive
phenotype.
to achieve a 50% reduction in plaque numbers relative to the
number of plaques obtained in the absence of mouse serum.
Included as a positive standard in each assay was a comple-
ment-dependent neutralizing monoclonal antibody (designat-
ed AP7) which is directed against HSV-1 glycoprotein D (13).
Delayed-type hypersensitivity (DTH) assays. Groups of six
mice were vaccinated in the left ear pinna with either the live
SC16AgH mutant, inactivated SC16AgH, or live wtSC16 at the
doses indicated in Fig. 4. A control group of mice was
inoculated with PBS only. At 14 days postvaccination, mice
were challenged with 106 PFU of wtSC16 by scarification of the
right ear pinna. The thicknesses of both ears were measured at
24 and 48 h postchallenge. The results are expressed as
differences in thickness between challenged and unchallenged
ears.
RESULTS
Determination of the level of nondefective virus in SC16AgH
progeny. Replication-defective deletion mutants are occasion-
ally rescued by recombination with the viral gene resident in
the helper cell line. Before initiating protection experiments, it
was therefore important to determine the levels of nondefec-
tive virus in SC16AgH virus stocks and to assess the possible
impact of this component on the experiments. Following two
rounds of cloning by limiting dilution, working stocks of
SC16AgH virus were titrated on gH-inducible F6 cells and on
Vero cells and the relative titers were estimated as approxi-
mately 5 x 106:1. Plaques formed in Vero cells were f-galac-
tosidase negative, implying that the nondefective phenotype
had resulted from replacement of the lacZ gene by the
gH-encoding gene resident in the cell line. Mice were then
infected by the ear route with 5 x 107 PFU of SC16AgH virus,
and titers at the inoculation site and in innervating dorsal root
ganglia were measured by plaque assay on F6 cells. The results
are shown in Fig. 1, in which, for comparison, the virus titers
resulting from parallel infections with 5 x 105 PFU (i.e., a
100-fold lower dose) of SC16AUs5 are also shown. One day
after infection, less than 0.01% of the input SC16AgH inocu-
lum was recovered from the inoculation site and this residual
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inoculum was cleared during the subsequent 7 days. No
infectivity was recovered from dorsal root ganglia. All of the
detectable virus had the f-galactosidase-positive phenotype
and was not detected by assay on BHK-21 cells. Thus, although
each animal received an estimated 10 PFU of replication-
competent virus, this component was never detected and was
presumably overwhelmed by the huge excess of defective virus.
Histological examination revealed that after 5 days, when only
about 0.0001% of the input inoculum can be detected, large
numbers of 3-galactosidase-positive cells were present at the
inoculation site (Fig. 2a). Thus, inoculation with phenotypi-
cally gH+ virus had successfully established infection but, in
contrast to the SC16AUs5 virus (Fig. 2b), had not spread
beyond the inoculation site. At 1 month after infection, the clI,
cIll, and cIV dorsal root ganglia were dissected from 12 mice
infected with SC16AgH and were incubated in tissue culture
medium for 5 days to allow reactivation of latent virus. The
tissue was then homogenized and assayed for infectivity. None
was found.
Induction of protective immunity by SC16AgH virus. Exper-
iments were designed to compare the protective efficacy of
equivalent doses of inactivated virus with that of replication-
defective virus over a broad dose range. Protection was
assessed by measuring the growth of wild-type virus in the ear
pinna 5 days after challenge, the point at which peak titers are
observed in this model (Fig. 1). Groups of four mice were
vaccinated by left-ear scarification with SC16AgH or ,B-propio-
lactone-inactivated virus at doses ranging from 5 x 102 to 5 x
107 PFU. The particle-infectivity ratio of the purified virus
preparation was approximately 30:1, and the maximum dose
used therefore was about 109 virions, equivalent to about 1 ,ug
of virion protein. After 14 days, mice were challenged by
inoculation of the right ear with 2 x 106 PFU of wtSC16. The
results of two experiments are shown in Fig. 3, which gives the
geometric mean titers of challenge virus 5 days after inocula-
tion. At the higher doses used, vaccination with live SC16AgH
or with inactivated virus resulted in complete clearance of the
challenge virus at 5 days postinfection, while at the lower dose
no effect was observed with live or killed vaccine. At all
intermediate doses, vaccination with the live gH- virus sup-
pressed challenge virus growth with greater efficiency. Com-
parison of the data suggests that a 100-fold-higher dose of
inactivated virus is required to achieve an equivalent effect in
this assay.
Induction of neutralizing antibodies by the SC16AgH mu-
tant. Although different studies have suggested different mech-
anisms of immunity to HSV challenge, a comparison of the
efficacies of different glycoprotein antigens delivered with a
live vector suggested that protection correlated with neutral-
izing antibody induction. Injection with a live gH-negative virus
results in a single-cycle infection and significant amplification
of the delivered antigen compared with vaccination with an
equivalent dose of killed virus. We therefore predicted higher
neutralizing antibody titers in animals that received SC16AgH
than in those that received inactivated virions. Serum samples
taken from individual mice prior to challenge in the protection
experiment shown in Fig. 3 (experiment 2) were assayed for
neutralizing antibody to HSV-1 (Table 1). At the lowest
vaccine dose for which sera were tested (5 x 104 PFU),
SC16AgH infection induced detectable neutralizing antibody,
whereas inactivated virions did not. Nevertheless, the neutral-
izing antibody titers in the sera of mice that received higher
vaccine doses were not significantly different and it seems
unlikely that preexisting antibody titers can account for the
considerable difference in protection afforded by vaccination
with the live disabled virus and the inactivated virus. For
comparison, the neutralizing antibody titers of animals injected
in parallel with 2 x 106 PFU of wtSC16 are shown. This dose
of wild-type virus affords complete protection against subse-
quent challenge with the same dose. As expected, the antibody
titers induced in these animals were higher although not
dramatically so.
Induction of DTH responses by the SC16AgH mutant. It is
widely accepted that T-cell responses are crucial in controlling
HSV infection, and while uncertainty remains as to the relative
contributions of different T-cell subsets, there is strong evi-
dence that CD4+ T-cell responses are effective in virus clear-
ance in the mouse ear model. DTH responses to wtSC16 in
vaccinated mice were therefore measured as described in
Materials and Methods. The experimental design was similar
to that described for the protection study in that a range of
doses of the vaccinating virus was employed and the responses
induced by equivalent doses of an inactivated vaccine were
included for comparison. In addition, groups of mice which
received equivalent doses of wtSC16 as the vaccinating virus
were also included. The results are presented in Fig. 4. At
vaccinating doses of 5 x 103 and 5 x 104 PFU, the SC16AgH
mutant induced DTH responses at levels on day 2 postinfec-
tion which were comparable to those induced by wtSC16, while
the inactivated vaccine at these doses was completely ineffec-
tive. In a separate experiment, a dose of 102 PFU of either the
live-disabled or killed vaccine failed to elicit a DTH response
(data not shown). Nevertheless, DTH responses were detected
in mice given higher doses of the inactivated vaccine, with
responses which were equivalent to those induced by the
SC6I gH mutant at the highest vaccine dose used. While these
results do not, of course, show that the basis of the efficacy of
a live disabled virus, by comparison with a killed virus, lies in its
ability specifically to induce a DTH response, they are consis-
tent with the general view that a live vaccine recruits a T-cell
response more efficiently than does an equivalent dose of killed
antigen.
DISCUSSION
It is generally accepted that live vaccines offer considerable
advantages over killed or subunit vaccines in terms of both the
range of responses induced and the longevity of the response.
The ability of HSV to establish life-long latency is, however, a
significant issue in contemplating human vaccination with an
attenuated HSV. A disabled virus capable of a single cycle of
infection may be an attractive alternative. The findings pre-
sented here demonstrate that the SC16AgH HSV-1 mutant is
able to establish a self-limiting infection in vivo that induces
both humoral and T-cell responses and protects mice against
subsequent challenge with wild-type HSV-1. Low doses of the
SC16AgH mutant induced levels of DTH responses in mice
which were comparable to those induced following infection
with wtSC16. In addition, the SC16AgH virus elicited neutral-
izing antibodies with titers which remain elevated well beyond
clearance of the virus from the animals. In comparison with an
inactivated vaccine, the SC16AgH mutant was more effective in
inducing DTH responses and in conferring protection during
acute infection. Although live-virus vaccines have been shown
to elicit cellular immunity more readily than killed-virus or
subunit vaccines, the mechanism(s) by which this is achieved is
unknown. A simple explanation for our results is that the
amplification of viral genes produced during the single cycle of
replication of the SC16AgH mutant in vivo and the natural
presentation of appropriate viral targets elicit responses which,
in both quantity and quality, are more effective in conferring
protection than are the responses induced by killed-virus
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FIG. 2. Histological demonstration of cells infected with HSV-1 lacZ insertional mutants in mice (magnification, x 160). Sections of the ear
pinnae of mice infected 5 days previously with either SC16AgH (a) or SC16AUS5 (b) were examined microscopically after being stained with
X-Gal.
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FIG. 3. Clearance of wtSC16 in the ears of mice vaccinated with
either SC16AgH or ,B-propiolactone-inactivated wtSC16. Groups of
four mice were vaccinated at the doses indicated by scarification of the
left ear pinna. Control mice were given saline only. Mice were
challenged 14 days postvaccination with 2 x 106 PFU of wtSC16 in the
right ear pinna, and virus titers were measured at 5 days postinfection.
The data are expressed as geometric means and the standard errors of
the means. Asterisks indicate that virus was not detected. In cases in
which virus was not recovered from four of four mice, the numbers of
mice from which virus was recovered are indicated above the error
bars.
vaccines. However, the protection afforded by the submicro-
gram doses of killed-virus vaccine illustrates the relative ease
with which protection may be achieved in the mouse model.
Further work is required to quantify the immune responses
generated by this single-cycle vaccine and to determine, by
adoptive transfer, which of the responses afford protection.
Furthermore, while mice have unique advantages in studies of
immune responses, HSV infection in guinea pigs is appropriate
for studies of reactivation and recrudescence and experiments
are now in progress to evaluate the vaccine potential of a
single-cycle virus in this animal model.
Similar studies addressing the vaccine potential of disabled
HSV-1 mutants were reported by Nguyen et al. (15), who
demonstrated that cellular immunity to HSV-1 and protection
from lethal challenge in mice could be achieved by vaccination
with replication-defective HSV-1 mutants. The magnitude of
TABLE 1. Quantification of neutralizing antibodies to HSV-1 in
mice vaccinated with either live SC16AgH or inactivated wtSC16
Vaccine dose Neutralizing antibody titera at:Vaccine (PFU) 14 days 3 mo
Live SC16AgH 0 <50 <50
5 x 104 79 ± 29 NDb
5 x 105 158 ± 58 ND
5 x 106 400 ± 0 500 ± 178
2 x 107 630 ± 162 ND
Inactivated wtSC16 0 <50 <50
5 x 104 <50 ND
5 x 105 100 ± 37 ND
5 x 106 500 ± 257 912 ± 130
2 x 107 400 ± 0 ND
Live wtSC16 2 x 106 1,600 + 585 1,600 + 0
a Each individual titer is expressed as the geometric mean of the reciprocal
dilution (plus 1 standard deviation) of serum required to neutralize 50% of the
virus infectivity obtained in the absence of antibody.6 ND, not done.
Day p.i. Day p.i.
FIG. 4. DTH responses in mice vaccinated with PBS (Lii),
SC16AgH (0), ,B-propiolactone-inactivated SC16AgH (O), or wtSC16
(-). Mice were vaccinated in the left ear pinna at the doses indicated
14 days prior to challenge with 106 PFU of wtSC16 in the opposite ear.
Note that wtSC16 was not used at the highest vaccine dose (5 x 106
PFU), since this is a lethal dose for 5-week-old BALB/c mice. Ear
thickness was measured 24 and 48 h postchallenge and is expressed as
the difference between the challenged and vaccinated ears. The data
are presented as mean differences in ear thickness and the standard
errors of the means. p.i., postinfection.
T-cell responses to these mutants was proportional to the
extent to which viral gene expression occurred in infected cells.
However, the replication-defective mutants used in their study
were deficient in the expression of all or some of the late gene
products, many of which are known to be targets for antibodies
and T cells (3, 8, 10, 12). In contrast, infection of cells with the
phenotypically gH-positive SC16zAgH mutant results in a rep-
licative cycle that is normal in all respects except that the
progeny are noninfectious. Therefore, we can presume that the
SC16AgH mutant has the capacity to elicit immune responses
with a range of specificities (with the exception of responses to
gH) comparable with those induced by the parental wild-type
virus.
Given that the SC16AgH virus is incapable of producing
infectious progeny in cells that are unable to provide gH in
trans, it is unlikely that infection could spread beyond the cells
surrounding the vaccination site in vivo. However, given that
disabled HSV-1 mutants have been previously shown to estab-
lish a latent infection, it is possible that the SC16zAgH virus can
establish a latent infection as a result of direct entry into
sensory nerve endings by the input inoculum. Indeed, prelim-
inary experiments have identified the major latency-associated
transcript in the cervical ganglia of mice vaccinated with the
SC16AgH virus (data not shown). Although detection of the
lacZ gene is required for formal proof that the SC16AgH virus
resides in sensory ganglia, numerous attempts to reactivate
virus from infected animals have proved unsuccessful, implying
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that the latent virus is unable to produce infectious virus upon
reactivation. Furthermore, attempts to rescue 3-galactosidase-
positive virus by superinfection of latently infected ganglia in
vitro were also unsuccessful.
In conclusion, our studies demonstrate that the SC16gH
mutant is able to stimulate protective immune responses
without the risk of virus dissemination associated with live
attenuated HSV vaccines. Although the SC16AgH mutant may
have the propensity to establish a latent infection, reactivation
of the latent virus could result only in the production of
noninfectious virus. This vaccination strategy may also be
applied to systems in which HSV-1 is used as a live vector for
expression of heterologous genes.
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